18-FDG PET in the staging and follow-up of lymphoma patients: Comparison with clinical and radiologic findings(95 visite) Mainolfi C, Maurea S, Varrella P, Alaia C, Imparato C, Alfano B, Abate G, Bazzicalupo L
Radiol Med (ISSN: 1826-6983, 0033-8362, 1826-6983electronic), 1998; 95(1-2): 98-104.
Tipo di articolo: Journal Article,
Impact factor: 0.967, Impact factor a 5 anni: 1.448
Parole chiave: Lymphomas, Diagnostic Imaging, Fdg Pet, Article, Cancer Localization, Cancer Staging, Diagnostic Value, Hodgkin Disease, Human, Major Clinical Study, Nonhodgkin Lymphoma, Positron Emission Tomography, Comparative Study, Computer Assisted Emission Tomography, Female, Follow Up, Radiography, Scintiscanning, Diagnostic Agent, Fluorodeoxyglucose F 18, Radiopharmaceutical Agent, Follow-Up Studies, Non-Hodgkin, Neoplasm Staging, Emission-Computed,
Affiliazioni:
Medicina Nucleare, Ctro. Med. Nucl. Cons. Naz. R., Univ. degli Studi Federico II, Napoli, Italy Via Raffaele De Cesare 7, 80132 Napoli NA, Italy
Riferimenti:
Bekerman, C., Hoffer, P.B., Bitran, J.D., The role of gallium-67 in the clinical evaluation of cancer (1984) Semin Nucl Med, 14, pp. 296-32
Bergonzini, R.E., Vezzolt, G., Rossi, G., I linfomi maligni a localizzazione toracica: Problemi di semeiologia e stadiazione radiologica (1988) Radiol Med, 76, pp. 56-63
Ellert, J., Kreel, L., The role of Computed Tomograph in the initial and subsequent management of the lymphomas (1980) JCAT, 4, pp. 368-391
Gasparini, M., Indicatori a tropismo tumorale (1994) Progressi Della Medicina Nucleare in Oncologia, pp. 129-175. , Buraggi GL, Bombardieri E (eds): Clas International. Brescia
Hatanaka, M., Transport of sugars in tumor cell membranes (1974) Biochem Biophys Acta, 355, pp. 77-104
Hoh, C.K., Glaspy, J., Rosen, P., Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphomas (1997) J Nucl Med, 38, pp. 343-348
Martiat, Ph., Ferrant, A., Labar, D., In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography (1988) J Nucl Med, 29, pp. 1633-1637
Negendank, W.G., Al-Katib, A.M., Karanes, C., Lymphomas: MR Imaging contrast characteristics with clinical pathological correlations (1990) Radiology, 177, pp. 209-216
Newman, J.S., Francis, I.R., Kaminski, M.S., Imaging of lymphoma with PET with 2-F-18-fluoro-2-deoxy-D-glucose: Correlation with CT (1994) Radiology, 190, pp. 111-116
Paul, R., Comparison of Fluorine-18-2-Fluorodeoxygiucose and gallium-67 citrate imaging for detection of lymphoma (1987) J Nucl Med, 28, pp. 288-292
Rigo, P., Paulus, P., Kaschten, B.J., Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose (1996) Eur J Nucl Med, 23, pp. 1641-1674
Schonberger, J.A., Stollfuss, J.C., Kocher, F., Whole-body 18-FDG-PET for staging of malignant lymphomas (1994) Eur J Nucl Med, 21, p. 727
Leskinen-Kallio, S., Ruotsalainen, U., Nagren, K., Uptake of carbon-11-Methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study (1991) J Nucl Med, 32, pp. 1211-1218
Strauss, L.G., Conti, P.S., The applications of PET in clinical oncology (1991) J Nucl Med, 32, pp. 623-648
Turner, D.A., Fordham, E., Ali, A., Gallium 67 imaging in the management of Hodgkin's disease and other malignant lymphomas (1978) Semin Nucl Med, 8, pp. 205-218
Valk, P.E., Pounds, T.R., Tesar, R.D., Cost-effectiveness of PET imaging in clinical oncology (1996) Nucl Med Biol, 23, pp. 737-743
Wahl, R.L., Hawkins, R.A., Larson, S.M., Proceeding of a national cancer institute workshop: PET in oncology - A clinical research agenda (1994) Radiology, 193, pp. 604-606
Wahl, R.L., Hutchins, G.D., Buchsboaum, D.J., 18-F-2-deoxy-2-fluoro-deoxyglucose uptake into human tumor xenografts (1991) Cancer, 67, pp. 1544-1550
Warburg, O., On the origin of cancer cells (1956) Science, 123, pp. 309-314
Weinhous, S., Changing perceptions of carbohydrate metabolism in tumors (1981) Molecular Interrelations of Nutrition and Cancer, pp. 167-181. , Arnott MS, Van Eys SJ, Wary JM (eds): Raven Press. New York
Bergonzini, R. E., Vezzolt, G., Rossi, G., I linfomi maligni a localizzazione toracica: Problemi di semeiologia e stadiazione radiologica (1988) Radiol Med, 76, pp. 56-63
Hoh, C. K., Glaspy, J., Rosen, P., Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphomas (1997) J Nucl Med, 38, pp. 343-348
Negendank, W. G., Al-Katib, A. M., Karanes, C., Lymphomas: MR Imaging contrast characteristics with clinical pathological correlations (1990) Radiology, 177, pp. 209-216
Newman, J. S., Francis, I. R., Kaminski, M. S., Imaging of lymphoma with PET with 2-F-18-fluoro-2-deoxy-D-glucose: Correlation with CT (1994) Radiology, 190, pp. 111-116
Schonberger, J. A., Stollfuss, J. C., Kocher, F., Whole-body 18-FDG-PET for staging of malignant lymphomas (1994) Eur J Nucl Med, 21, p. 727
Strauss, L. G., Conti, P. S., The applications of PET in clinical oncology (1991) J Nucl Med, 32, pp. 623-648
Turner, D. A., Fordham, E., Ali, A., Gallium 67 imaging in the management of Hodgkin's disease and other malignant lymphomas (1978) Semin Nucl Med, 8, pp. 205-218
Valk, P. E., Pounds, T. R., Tesar, R. D., Cost-effectiveness of PET imaging in clinical oncology (1996) Nucl Med Biol, 23, pp. 737-743
Wahl, R. L., Hawkins, R. A., Larson, S. M., Proceeding of a national cancer institute workshop: PET in oncology - A clinical research agenda (1994) Radiology, 193, pp. 604-606
Wahl, R. L., Hutchins, G. D., Buchsboaum, D. J., 18-F-2-deoxy-2-fluoro-deoxyglucose uptake into human tumor xenografts (1991) Cancer, 67, pp. 1544-1550
Introduction. The clinical applications of fluorine-18-deoxyglucose Positron Emission Tomography (FDG PET) have been proposed on account of experimental evidence of increased glucose metabolism in tumor cells. Material and methods. We examined 98 lymphoma patients - 33 with Hodgkin and 65 with non-Hodgkin disease - with FDG PET and compared its findings with those of clinical and conventional radiologic studies. FDG PET was also used to follow-up 32 patients and the results were once again compared with clinical and radiologic data. Results. During staging, 138 lesions were found, 82 of them (59%) in nodal and 56 (41%) in extranodal locations. Extranodal tumor sites were found in 39 patients (40%), namely 4 with Hodgkin (12%) and 35 with non-Hodgkin (54%) disease. FDG PET findings were in agreement with clinical and radiologic results in all nodal and extranodal lesions, since all of them exhibited abnormally increased FDG uptake. PET detected new tumor sites in 6 patients. In the follow-up, agreement was observed in the majority (78%) of lesions, 30 of them in complete regression, 15 in partial regression and 17 in progression; however, the diagnostic results were in disagreement in the remaining (22%) tumor sites: no abnormal FDG uptake was found in 9 cases despite the persistence of radiologic abnormalities (post-treatment fibrosclerosis). Slightly increased FDG uptake (residual disease) was found in the other 8 lesions, where there was no clinical and/or radiologic evidence of disease. Conclusions. FDG PET is a functional imaging technique useful to diagnose lymphomas and providing metabolic characterization of cancer abnormalities. Whole body PET permits the simultaneous assessment of nodal and extranodal lymphoma localizations. During the follow-up, FDG PET permits better monitoring of treatment effects than clinical and radiologic examinations.
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(163 visite) Parkinsonism Relat Disord (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 DettagliEsporta in BibTeXEsporta in EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(115 visite) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 DettagliEsporta in BibTeXEsporta in EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(305 visite) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 DettagliEsporta in BibTeXEsporta in EndNote
354 Records (333 escludendo Abstract e Conferenze). Impact factor totale: 1058.066 (1011.041 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 1160.573 (1101.918 escludendo Abstract e Conferenze).
ibb.cnr.it